1. Javitt , DC , Zukin , SR . Recent advances in the phencyclidine model of schizophrenia . Am J Psychiatry 1991 ; 148 : 1301 – 1308 .

2. Olney , JW , Farber , NB . NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia . Neuropsychopharmacology 1995 ; 13 : 335 – 345 .

3. Coyle , JT . The glutamatergic dysfunction hypothesis for schizophrenia . Harv Rev Psychiatry 1996 ; 3 : 241 – 253 .

4. Krystal , JH , D’Souza , DC , Petrakis , IL et al . NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders . Harv Rev Psychiatry 1999 ; 7 : 125 – 143 .

5. Hashimoto , K , Okamura , N , Shimizu , E , Iyo , M . Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs . Cent Nerv Syst Agents Med Chem 2004 ; 4 : 147 – 154 .

6. Hashimoto , K , Shimizu , E , Iyo , M . Dysfunction of glia-neuron communication in pathophysiology of schizophrenia . Curr Psychiatry Rev 2005 ; 1 : 151 – 163 .

7. Hashimoto , K . The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs . Clin Psychopharmacol Neurosci 2006 ; 4 : 3 – 10 .

8. Hashimoto , K , Malchow , B , Falkai , P , Schmitt , A . Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders . Eur Arch Psychiatry Clin Neurosci 2013 ; 263 : 367 – 377 .

9. Hashimoto , K . Targeting of NMDA receptors in new treatments for schizophrenia . Expert Opin Ther Targets 2014 ; 18 : 1049 – 1063 .

10. Krystal , JH , Karper , LP , Seibyl , JP et al . Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses . Arch Gen Psychiatry 1994 ; 51 : 199 – 214 .

11. Krystal , JH , Perry , EB Jr , Gueorguieva , R et al . Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function . Arch Gen Psychiatry 2005 ; 62 : 985 – 994 .

12. Anand , A , Charney , DS , Oren , DA et al . Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl- d- aspartate receptor antagonists . Arch Gen Psychiatry 2000 ; 57 : 270 – 276 .

13. Jentsch , JD , Roth , RH . The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia . Neuropsychopharmacology 1999 ; 20 : 201 – 225 .

14. Hashimoto , K , Fujita , Y , Shimizu , E , Iyo , M . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol . Eur J Pharmacol 2005 ; 519 : 114 – 117 .

15. Hashimoto , K , Fujita , Y , Ishima , T , Hagiwara , H , Iyo , M . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α7 nicotinic receptors . Eur J Pharmacol 2006 ; 553 : 191 – 195 .

16. Hashimoto , K , Fujita , Y , Iyo , M . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors . Neuropsychopharmacology 2007 ; 32 : 514 – 521 .

17. Hashimoto , K , Fujita , Y , Ishima , T , Chaki , S , Iyo , M . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d- serine . Eur Neuropsychopharmacol 2008 ; 18 : 414 – 421 .

18. Hashimoto , K , Ishima , T , Fujita , Y et al . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711 . Biol Psychiatry 2008 ; 63 : 92 – 97 .

19. Hagiwara , H , Fujita , Y , Ishima , T et al . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors . Eur Neuropsychopharmacol 2008 ; 18 : 448 – 454 .

20. Tanibuchi , Y , Fujita , Y , Kohno , M et al . Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of α1-adrenoceptors . Eur Neuropsychopharmacol 2009 ; 19 : 861 – 867 .

21. Fujita , Y , Ishima , T , Kunitachi , S et al . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline . Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32 : 336 – 339 .

22. Shirai , Y , Fujita , Y , Hashimoto , K . Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration . Clin Psychopharmacol Neurosci 2012 ; 10 : 94 – 98 .

23. Coyle , JT , Tsai , G . The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia . Psychopharmacology (Berl) 2004 ; 174 : 32 – 38 .

24. Ferraris , DV , Tsukamoto , T . Recent advances in the discovery of d- amino acid oxidase inhibitors and their therapeutic utility in schizophrenia . Curr Pharm Des 2011 ; 17 : 103 – 111 .

25. Labrie , V , Wong , AH , Roder , JC . Contributions of the d- serine pathway to schizophrenia . Neuropharmacology 2012 ; 62 : 1484 – 1503 .

26. Hashimoto , K , Fukushima , T , Shimizu , E et al . Decreased serum levels of d- serine in patients with schizophrenia: evidence in support of the N-methyl- d- aspartate receptor hypofunction hypothesis of schizophrenia . Arch Gen Psychiatry 2003 ; 60 : 572 – 576 .

27. Hashimoto , K , Engberg , G , Shimizu , E , Nordin , C , Lindstrom , LH , Iyo , M . Reduced d- serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients . Prog Neuropsychopharmacol Biol Psychiatry 2005 ; 29 : 767 – 769 .

28. Yamada , K , Ohnishi , T , Hashimoto , K et al . Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d- serine levels . Biol Psychiatry 2005 ; 57 : 1493 – 1503 .

29. Bendikov , I , Nadri , C , Amar , S et al . A CSF and postmortem brain study of d- serine metabolic parameters in schizophrenia . Schizophr Res 2007 ; 90 : 41 – 51 .

30. Calcia , MA , Madeira , C , Alheira , FV et al . Plasma levels of d- serine in Brazilian individuals with schizophrenia . Schizophr Res 2012 ; 142 : 83 – 87 .

31. Tsai , G , Yang , P , Chung , LC , Lange , N , Coyle , JT . d- serine added to antipsychotics for the treatment of schizophrenia . Biol Psychiatry 1998 ; 44 : 1081 – 1089 .

32. Heresco-Levy , U , Javitt , DC , Ebstein , R et al . d- Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia . Biol Psychiatry 2005 ; 57 : 577 – 585 .

33. Kantrowitz , JT , Malhotra , AK , Cornblatt , B et al. . High dose d- serine in the treatment of schizophrenia . Schizophr Res 2010 ; 121 : 125 – 130 .

34. Weiser , M , Heresco-Levy , U , Davidson , M et al . A multicenter, add-on randomized controlled trial of low-dose d- serine for negative and cognitive symptoms of schizophrenia . J Clin Psychiatry 2012 ; 73 : e728 – e734 .

35. Ermilov , M , Gelfin , E , Levin , R et al . A pilot double-blind comparison of d- serine and high-dose olanzapine in treatment-resistant patients with schizophrenia . Schizophr Res 2013 ; 150 : 604 – 605 .

36. Tsai , GE , Lin , PY . Strategies to enhance N-methyl- d- aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis . Curr Pharm Des 2010 ; 16 : 522 – 537 .

37. Verrall , L , Walker , M , Rawlings , N et al . d- Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia . Eur J Neurosci 2007 ; 26 : 1657 – 1669 .

38. Madeira , C , Freitas , ME , Vargas-Lopes , C , Wolosker , H , Panizzutti , R . Increased brain d- amino acid oxidase (DAAO) activity in schizophrenia . Schizophr Res 2008 ; 101 : 76 – 83 .

39. Chumakov , I , Blumenfeld , M , Guerassimenko , O et al . Genetic and physiological data implicating the new human gene G72 and the gene for d- amino acid oxidase in schizophrenia . Proc Natl Acad Sci USA 2002 ; 99 : 13675 – 13680 .

40. Kvajo , M , Dhilla , A , Swor , DE , Karayiorgou , M , Gogos , JA . Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function . Mol Psychiatry 2008 ; 13 : 685 – 696 .

41. Detera-Wadleigh , SD , McMahon , FJ . G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis . Biol Psychiatry 2006 ; 60 : 106 – 114 .

42. Klein , JR , Kamin , H . Inhibition of the d- amino acid oxidase by benzoic acid . J Biol Chem 1941 ; 138 : 507 – 512 .

43. Ferraris , D , Duvall , B , Ko , YS et al . Synthesis and biological evaluation of d- amino acid oxidase inhibitors . J Med Chem 2008 ; 51 : 3357 – 3359 .

44. Lane , HY , Lin , CH , Green , MF et al . Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of d- amino acid oxidase inhibitor . JAMA Psychiatry 2013 ; 70 : 1267 – 1275 .

45. Hashimoto , K , Engberg , G , Shimizu , E , Nordin , C , Lindstrom , LH , Iyo , M . Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients . BMC Psychiatry 2005 ; 5 : 6 .

46. Hashimoto , K . Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain . Schizophr Res 2014 ; 156 : 281 – 282 .

47. Zhang , L , Shirayama , Y , Iyo , M , Hashimoto , K . Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine . Neuropsychopharmacology 2007 ; 32 : 2004 – 2010 .

48. Hashimoto , K , Fujita , Y , Horio , M et al . Co-administration of a d- amino acid oxidase inhibitor potentiates the efficacy of d- serine in attenuating prepulse inhibition deficits after administration of dizocilpine . Biol Psychiatry 2009 ; 65 : 1103 – 1106 .

49. Horio , M , Fujita , Y , Ishima , T et al . Effects of d- amino acid oxidase inhibitor on the extracellular d- alanine levels and the efficacy of d- alanine on dizocilpine-induced prepulse inhibition deficits in mice . Open Clin Chem J 2009 ; 2 : 16 – 21 .

50. Ren , Q , Zhang , JC , Fujita , Y , Ma , M , Wu , J , Hashimoto , K . Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine . Pharmacol Biochem Behav 2013 ; 106 : 124 – 127 .

51. Fukushima , T , Kawai , J , Imai , K , Toyo’oka , T . Simultaneous determination of d- and l -serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection . Biomed Chromatogr 2004 ; 18 : 813 – 819 .

52. Aoyama , C , Santa , T , Tsunoda , M , Fukushima , T , Kitada , C , Imai , K . A fully automated amino acid analyzer using NBD-F as a fluorescent derivatization reagent . Biomed Chromatogr 2004 ; 18 : 630 – 636 .

53. Horio , M , Kohno , M , Fujita , Y et al . Levels of d- serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice . Neurochem Int 2011 ; 59 : 853 – 859 .

54. Smith , SM , Uslaner , JM , Hutson , PH . The therapeutic potential of d- Amino acid oxidase (DAAO) inhibitors . Open Med Chem J 2010 ; 4 : 3 – 9 .

55. Sacchi , S , Rosini , E , Pollegioni , L , Molla , G . d- Amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy . Curr Pharm Des 2013 ; 19 : 2499 – 2511 .

56. Hashimoto , K . Comments on ‘The effect of risperidone on d- amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia’ . J Psychopharmacol 2010 ; 24 : 1133 – 1134 .

57. Jana , A , Modi , KK , Roy , A , Anderson , JA , van Breemen , RB , Pahan , K . Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders . J Neuroimmune Pharmacol 2013 ; 8 : 739 – 755 .

58. Ren , Q , Zhang , JC , Ma , M , Fujita , Y , Wu , J , Hashimoto , K . 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine . Psychopharmacology (Berl) 2014 ; 231 : 159 – 166 .

59. Hashimoto , K . Microglial activation in schizophrenia and minocycline treatment . Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32 : 1758 – 1759 . author reply 1760.

60. Matsuzawa , D , Hashimoto , K . Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia . Antioxid Redox Signal 2011 ; 15 : 2057 – 2065 .

61. Yao , JK , Keshavan , MS . Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view . Antioxid Redox Signal 2011 ; 15 : 2011 – 2035 .

62. Kirkpatrick , B , Miller , BJ . Inflammation and schizophrenia . Schizophr Bull 2013 ; 39 : 1174 – 1179 .

63. Steullet , P , Cabungcal , JH , Monin , A et al . Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophr Res 2014 , doi:10.1016/j.schres.2014.06.021.

64. Brahmachari , S , Jana , A , Pahan , K . Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses . J Immunol 2009 ; 183 : 5917 – 5927 .

65. Khasnavis , S , Pahan , K . Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons . J Neuroimmune Pharmacol 2012 ; 7 : 424 – 435 .

66. Zhang , L , Kitaichi , K , Fujimoto , Y et al . Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine . Prog Neuropsychopharmacol Biol Psychiatry 2006 ; 30 : 1381 – 1393 .